Rick just exited more options worth $13,712,301.00 Abbv stock is headed back to $60-$65 range... DUMP IT NOW.
Interview With Rick G. CEO Abbvie Inc.
- Thread starter anonymous
- Start date
-
- Tags
- None
193,131 shares dumped yesterday and $10.9M on 8/3 and 8/4 Follow the money trail.
Almost $24M in ABBV options dumped in LAST WEEK by gonzo.
Almost $24M in ABBV options dumped in LAST WEEK by gonzo.
$10,000 GONNA HAVE SOME FUN.....
PUT IT ALL ON....A HUNDRED TO ONE.....
YEEEEEHAWWWWW
PUT IT ALL ON....A HUNDRED TO ONE.....
YEEEEEHAWWWWW
Did Wicky finish up his schooling and complete his bachelors degree?
Why did Uncle Miles try to cover up this willful lie back in 2012 ? Shame on him !
Dear Colleague:
You may have seen news reports in recent days regarding Rick Gonzalez' educational background. I want to provide you with some facts so you do not have to rely only on news reports.
There was an error made when Rick's Company biography was originally written many years ago. It incorrectly stated that he had earned Bachelor's and Master's degrees. Rick brought this error to the Company's attention after his retirement and prior to returning to the Company in 2009. We conducted an internal and external investigation of the matter and his biography was subsequently corrected. We also discussed the matter with the Board of Directors prior to his selection to lead the new company. After full discussion, the Board and I concluded he is the right person to lead AbbVie.
I have worked with and known Rick for nearly 30 years. He is one of the finest leaders, businessmen and individuals I have known. He has managed and led our business with integrity and commitment to our patients, our employees and our shareholders. The Board and I are fully confident in him and his ability to lead AbbVie.
Sincerely,
Miles
Ricky just backtracked on his ludicrous statement/commitment to restrict annual price hikes to just under 10%. Gonzo now claims it only applies to 2017 and could be revisited in 2018. WTF Puppet Boy ?
Make your mind up. Your left hand dont know what your right hand is doing.
What pledge? AbbVie executives may back off their vow to limit price hikes: report
by Eric Sagonowsky |
Sep 25, 2017 9:37am
AbbVie executives, confident of its patent strength, think Humira can reach $20 billion in sales, according to an analyst report.
ShareFacebookTwitterLinkedInEmailPrint
Looking to combat the public drug-pricing backlash, AbbVie in January followed their peers in promising to hold the line at less than 10%. Now, though, they're thinking about reneging on that pledge.
That's the word from analysts at Leerink, who came away from a management meeting last week impressed enough to roll out a 14-page report detailing their upbeat outlook for AbbVie. Confident they can hold off Humira biosimilars until 2022, the company trotted out a $20 billion target for its best-selling drug, a figure higher than the full-company sales of some rival Big Pharmas.
And it didn't hurt that AbbVie executives said the company may revisit its pricing pledge, which could limit its ability to reap maximum sales from Humira as the end of its monopoly nears, a common strategy in the pharma business. Plus, price hikes have been an important growth driver at AbbVie, the analysts said.
As political and public drug pricing pressure threatened a regulatory overhaul in recent years, AbbVie joined many of its pharma competitors in committing to only raise prices once a year and at a level below 10%. But management now thinks pricing pressure is subsiding, according to the Leerink analysts.
AbbVie leadership believes the company "has the flexibility to revert to more than one price increase per year and to double-digit increases in 2018 and beyond," the analysts wrote after the meeting.
Allergan CEO Brent Saunders famously kicked off the pricing trend in a post last year about pharma's "social contract." Drugmakers including Novo Nordisk, AbbVie and Takeda and Sanofi followed up with pledges of their own.
RELATED: The decade's top 10 patent losses, worth a whopping $915B in lifetime sales
The pricing sentiment at AbbVie follows a prediction Bernstein analyst Ronny Gal made during an interview with FiercePharma last month. He said companies have so far stuck to the price-limiting strategy because "it works," but that could change.
“I’m guessing it will stay here until the noise comes down,” he said last month. “Then, someone will take a step up, and if there’s no response, more people will do it.”
Led by Humira, AbbVie management said during their Leerink meeting that the company's immunology franchise could approach $30 billion in annual sales. Other programs in the group include upadacitinib and risankizumab.
RELATED: The top 15 best-selling cancer drugs in 2022 - Venclexta
Outside of immunology, the company thinks it can get a combined $10 billion to $12 billion out of its hematology and oncology assets Imbruvica and Venclexta, according to the report. Venclexta, in fact, recently racked up new data expected to prompt an early filing for broader use of the drug. And the drugmaker expects other drug programs to enter the oncology fray through "internal and external sources," according to the report.
Neurology, the third component of AbbVie's strategy, should start making meaningful contributions in the middle of the next decade, the executives said.
Like other top biologics, AbbVie's Humira has been under a growing biosimilar threat, with Boehringer Ingelheim and Amgen boasting FDA approvals for Cyltezo and Amjevita, respectively. Due to AbbVie's patent defense, neither has launched. AbbVie last month sued Boehringer, arguing the German drugmaker's efforts to market a biosim infringes some of its patents. Humira is protected by more than 100 patents, according to the lawsuit.
RELATED: AbbVie files another Humira patent suit, this time against Boehringer Ingelheim
Before Boehringer's approval last month, Amgen's biosimilar won a U.S. green light last year—that company also faces a patent suit from AbbVie. Humira's web of patents is one big reason why many analysts don't see the big-selling brand fading away even though it's losing some protections.
In recent data compiled for FiercePharma, life science commercial intelligence firm Evaluate predicted the brand would reach $19 billion in peak annual sales and $179 billion in lifetime sales through 2022. Humira brought in $16 billion last year, or 63% of AbbVie's total revenue.
Other companies with Humira biosimilars in the works include Novartis’ Sandoz unit, Biogen and Fujifilm Kyowa Kirin Biologics. Each of those versions have advanced to regulators in Europe, according to press releases. Merck and Coherus also have biosims in development.
Read more on
Wifey is half naked in these pics. Jesus H Christ, what the hell is wrong with these people ?
Did Rick even graduate high school ? I May have to go look it up.
Diploma or not, the stocks cracking a hundred tomorrow GUARANTEED!
I must say that Abbvie employees are being treated very well.This is reflected in Ricks 86% CEO approval on Glassdoor along with the 3.5 star company rating. Rick also is in the highest rated CEO category coming in at #62.
Iam with you --- Make Abbvie Great Again
Let's GIT'R DONE FOLKS
Where's your loyal employees bonus from the billion dollar windfall ABBV will get from corporate tax reform ? Don't give too much though, I'm trying to break 20 in 2018, something you did 6 years ago. Hell, I may even break down and trade my Chevy in for a Bentley and I'll be on snob patrol
Uh, pardon me, do y'all have any grey poupon ?
How come Ricky didnt go to Swiss Alps Davos summit with Trump ? Vas Narasimhan who will be CEO of Novartis next week and current CEO of Bayer Werner Baumann where there mingling with Trump. Ricky could have discussed Humira price increase and made his case for raising it another 5%.
********************
Beg your pardon sir, where have you been?? Our CEO met with some senior Cabinet level officials over there. Yes Mr. G. was not at the 16 seat CEO roundtable but that was set up way early on and only the real big players got a seat. Rest assured he is on top of Humira pricing policy etc.
You can expect a very generous one time bonus check very soon.
Appreciate your concern.
*********************
My guess is he didn't go to Davos because he's embarrassed that he only attained a high school diploma. Also, he's getting rich and lazy in his old age.
STOP LYING !!!! He has degrees from Pacific Union University !!!!
AbbVie Inc. ABBV -2.11% said Friday the new U.S. tax overhaul will slash its effective tax rate to 9% for 2018 and yield savings the drugmaker said it would use to return cash to shareholders and boost employee compensation. Shares of AbbVie jumped 13.8%, to $123.21, adding about $24 billion to the market value of the North Chicago, Ill., maker of the multibillion-dollar arthritis drug Humira.
The 9% effective tax rate AbbVie expects for 2018 is down from about 18.9% in the fourth quarter of 2017. AbbVie Chief Financial Officer Bill Chase said the new tax law allows “more efficient” repatriation of future foreign earnings.
JPMorgan analyst Christopher Schott said AbbVie has relied on repatriating foreign earnings to help fund its stock dividend, and is now able to repatriate that money at a lower tax than under the old law. ”The company said the tax rate should inch back up to about 13% over the next five years because of increased U.S. income and investments.
Over the next five years, AbbVie plans to invest about $2.5 billion in capital projects in the U.S., and is evaluating additional expansion of its U.S. facilities, the company said.
Also, in 2018, the company plans to make a one-time charitable contribution of approximately $350 million to certain not-for-profit organizations based in the U.S., including rebuilding efforts for storm-ravaged Puerto Rico, Chief Executive Richard Gonzalez told analyst on a conference call.
AbbVie also said it plans to accelerate pension funding by $750 million, and enhance nonexecutive employee compensation.
Shareholders won’t be left out. The company said it is working on a plan to accelerate the growth of its stock dividend and repurchase more of its shares.
AbbVie reported improved fourth-quarter financial results and substantially boosted its expectation of full-year 2018 earnings to reflect the impact of the new U.S. tax law, which lowered the top corporate rate to 21% from 35%, and stronger operating performance. The company now expects full-year earnings, excluding certain items, of $7.33 to $7.43 a share, versus its prior view of $6.37 to $6.57 per share.
The 9% effective tax rate AbbVie expects for 2018 is down from about 18.9% in the fourth quarter of 2017. AbbVie Chief Financial Officer Bill Chase said the new tax law allows “more efficient” repatriation of future foreign earnings.
JPMorgan analyst Christopher Schott said AbbVie has relied on repatriating foreign earnings to help fund its stock dividend, and is now able to repatriate that money at a lower tax than under the old law. ”The company said the tax rate should inch back up to about 13% over the next five years because of increased U.S. income and investments.
Over the next five years, AbbVie plans to invest about $2.5 billion in capital projects in the U.S., and is evaluating additional expansion of its U.S. facilities, the company said.
Also, in 2018, the company plans to make a one-time charitable contribution of approximately $350 million to certain not-for-profit organizations based in the U.S., including rebuilding efforts for storm-ravaged Puerto Rico, Chief Executive Richard Gonzalez told analyst on a conference call.
AbbVie also said it plans to accelerate pension funding by $750 million, and enhance nonexecutive employee compensation.
Shareholders won’t be left out. The company said it is working on a plan to accelerate the growth of its stock dividend and repurchase more of its shares.
AbbVie reported improved fourth-quarter financial results and substantially boosted its expectation of full-year 2018 earnings to reflect the impact of the new U.S. tax law, which lowered the top corporate rate to 21% from 35%, and stronger operating performance. The company now expects full-year earnings, excluding certain items, of $7.33 to $7.43 a share, versus its prior view of $6.37 to $6.57 per share.
Over the next five years, AbbVie plans to invest about $2.5 billion in capital projects in the U.S., and is evaluating additional expansion of its U.S. facilities, the company said.
Expand what ? Manufacturing? R/D ? Corporate HQ ?
Key words in all these statements "Plans" and "evaluating"
Also, in 2018, the company plans to make a one-time charitable contribution of approximately $350 million to certain not-for-profit organizations based in the U.S., including rebuilding efforts for storm-ravaged Puerto Rico, Chief Executive Richard Gonzalez told analyst on a conference call.
$750M tax deduction for ABBV ? Exactly what non profit orgs ? ( I want to see list ) Why Puerto Rico ? Why not Florida and Texas ?
AbbVie also said it plans to accelerate pension funding by $750 million, and enhance nonexecutive employee compensation.
"Accelerate" C suite pensions ? And only enhance grade 16 and below ?
Shareholders won’t be left out. The company said it is working on a plan to accelerate the growth of its stock dividend and repurchase more of its shares.
Buyback billions of your own stock with corporate tax reform $$
Follow the money trail, it leads to Corporate Leechs banking 90% of Tax reform $$ and throwing rank and file a bone.
Expand what ? Manufacturing? R/D ? Corporate HQ ?
Key words in all these statements "Plans" and "evaluating"
Also, in 2018, the company plans to make a one-time charitable contribution of approximately $350 million to certain not-for-profit organizations based in the U.S., including rebuilding efforts for storm-ravaged Puerto Rico, Chief Executive Richard Gonzalez told analyst on a conference call.
$750M tax deduction for ABBV ? Exactly what non profit orgs ? ( I want to see list ) Why Puerto Rico ? Why not Florida and Texas ?
AbbVie also said it plans to accelerate pension funding by $750 million, and enhance nonexecutive employee compensation.
"Accelerate" C suite pensions ? And only enhance grade 16 and below ?
Shareholders won’t be left out. The company said it is working on a plan to accelerate the growth of its stock dividend and repurchase more of its shares.
Buyback billions of your own stock with corporate tax reform $$
Follow the money trail, it leads to Corporate Leechs banking 90% of Tax reform $$ and throwing rank and file a bone.